Zacks Bull and Bear of the Day Highlights: Onyx

Pharmaceuticals, National City, Amdocs, Citi Trends and Deutsche Bank 
CHICAGO--(BUSINESS WIRE)--August 07, 2008
Zacks Equity Research highlights Onyx Pharmaceuticals (Nasdaq:
ONXX) as the Bull of the Day and National City Corp. (NYSE: NCC) as
the Bear of the Day. In addition, Zacks Equity Research provides
analysis on Amdocs, Ltd. (NYSE: DOX), Citi Trends, Inc. (Nasdaq: CTRN)
and Deutsche Bank AG (NYSE: DB). 
Full analysis of all these stocks is available at 
Here is a synopsis of all five stocks: 
Bull of the Day: Onyx Pharmaceuticals (Nasdaq: ONXX) 
Onyx reported strong Nexavar sales in the second quarter of 2008.
This is mainly attributed to the market penetration in the liver
cancer market while Nexavar's market share in the kidney cancer market
has stabilized due to heavy competition from Pfizer and Wyeth. 
We believe Nexavar sales will continue to grow over the next
several years since the label has expanded to liver cancer. In
addition to the U.S. and EU, Nexavar has been approved in South Korea
and China for liver cancer. Nexavar has the potential to become a
blockbuster for Onyx. We maintain our Buy rating on Onyx shares with a
price target of $46 per shares. 
Bear of the Day: National City Corp. (NYSE: NCC) 
NCC's 2Q08 GAAP net loss of $2.45 per diluted share was
substantially worse than estimates, primarily due to higher loss
provisions and a non-cash goodwill impairment charge of $1.1 billion.
During the quarter, credit metrics deteriorated significantly and
net-interest income fell short of expectations. The company raised
$7.0 billion in capital and also reduced its quarterly dividend to
$0.01 per share, to strengthen its capital position. These actions
have resulted in significant dilution to the existing shareholders. 
Further, though, NCC has taken several initiatives to restructure
its mortgage operations, we continue to see elevated risks in NCC's
mortgage and residential development loan portfolio and expect higher
losses in the coming quarters. We are maintaining our Sell rating with
a six-month target price of $4.50 per share for NCC. 
Latest Posts on the Zacks Analyst Blog: 
Amdocs, Ltd. (NYSE: DOX) 
Amdocs Limited, a leading provider of CRM and billing software for
communications service providers, continues to demonstrate robust
performance supported by industry-leading technology integration
products for large-scale transformational projects and managed
The company's third quarter fiscal 2008 financial results (ending
June 30) were above our estimates. Amdocs retains a leading position
for billing and customer care management in the telecommunications
industry. Although management indicated caution concerning near-term
business performance based on global macro-economic conditions, we
believe the company's long-standing fundamentals have improved as
global telecom carriers' transition to converged and consolidated
customer management solutions. 
Citi Trends, Inc. (Nasdaq: CTRN) 
We expect Citi Trends to report strong results for the second
quarter due in large part to the government's stimulus package, and we
are increasing our sales and EPS estimates for the second quarter. The
company is a relatively small specialty retailer with enormous growth
potential as it begins to expand its stores across the country. It
offers a smart selection of reasonably-priced hip fashions that
continue to resonate with its core customer base. 
However, we do not believe that momentum will carry over into the
second half of the year, and we are reducing our estimates for the
second half of 2008 and 2009. Our 2008 estimates still fall within the
company's full-year earnings guidance of $1.10 to $1.15 per share. We
believe consensus estimates are too high for the second half of 2008
and expect those estimates to come down in the weeks ahead. As a
result, we are downgrading the stock from Buy to Hold. 
Deutsche Bank AG (NYSE: DB) 
We are continuing our Hold on Deutsche Bank. DB posted second
quarter earnings before nonrecurring items of 418 million, down 75%
from the year-ago quarter, but up sequentially from a 985 million loss
in the first quarter. 
This was below our estimate, as results reflected 2.3 billion in
asset markdowns at the Corporate and Investment Bank. Most other
segments performed reasonably well despite poor market conditions. In
addition, DB cut costs significantly and further reduced risk
exposures. We are lowering our EPADS (earnings per American Depositary
Receipt) estimates to $5.00 from $8.00 for 2008 and to $11.90 from
$14.15 for 2009. 
Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter: 
About the Bull and Bear of the Day 
Every day, the analysts at Zacks Equity Research select two stocks
that are likely to outperform (Bull) or underperform (Bear) the
markets over the next 3-6 months. 
About the Analyst Blog 
Updated throughout every trading day, the Analyst Blog provides
analysis from Zacks Equity Research about the latest news and events
impacting stocks and the financial markets. 
About Zacks Equity Research 
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term. 
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them
keen insights to developments that affect company profits and stock
performance. Recommendations and target prices are six-month time
Zacks "Profit from the Pros" e-mail newsletter provides highlights
of the latest analysis from Zacks Equity Research. Subscribe to this
free newsletter today by visiting 
About Zacks is a property of Zacks Investment Research, Inc., which
was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was the
formation of his proprietary stock picking system; the Zacks Rank,
which continues to outperform the market by nearly a 3 to 1 margin.
The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your
free subscription to Profit from the Pros at 
Visit for information about the
performance numbers displayed in this press release. 
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security. 
Mark Vickery
Press spacebar to pause and continue. Press esc to stop.